2020

18.05.2020 – Lonza Group AG

Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group

Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group

Basel, Switzerland, 18 May 2020 – Dr Moncef Slaoui has decided to step down from his position as a member of the Lonza Group Board of Directors, following his appointment to the role of Chief Advisor for the U.S. government's “Warp Speed” national vaccine program.

Lonza Group wishes Dr Slaoui every success in his new role.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

Lonza Contact Details

Media:
Dr. Sanna Fowler
Head of External Communications
+41 79 539 0615
sanna.fowler@lonza.com

Victoria Morgan
Head of Corporate Communications
+41 79 599 6260
victoria.morgan@lonza.com


Investor Relations:
Dirk Oehlers
Investor Relations Director
+41 79 421 1609
dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.


close